These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 22454535)

  • 1. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
    Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
    J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
    Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
    Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
    Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
    Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
    Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
    Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired and intrinsic resistance to vemurafenib in BRAF
    Zhang P; Kuil LE; Buil LCM; Freriks S; Beijnen JH; van Tellingen O; de Gooijer MC
    FEBS Open Bio; 2024 Jan; 14(1):96-111. PubMed ID: 37953496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
    Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
    BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T; Agarwal S; Elmquist WF
    J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S; Sane R; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.